1e
19
1
49
2
2
18
1b
1d
18
3a
82
1d
2 29
1d
25
Lawrence Nathan Shulman, MD
78
82
Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
28
7a
3
5f
Co-Director, Center for Global Oncology, University of Pennsylvania
95
CGH Scholar, Center for Global Health, Perelman School of Medicine, University of Pennsylvania
8f
Associate Director, Special Projects, Abramson Cancer Center, University of Pennsylvania
99
Director of Faculty Mentorship, Penn Center for Cancer Care Innovation, University of Pennsylvania
8d
Innovation Faculty, Penn Center for Cancer Care Innovation, University of Pennsylvania
11
Department: Medicine
4
1
b
1d
46
Contact information
44
4
3
3
3
2
4
b
1f
44
Abramson Cancer Center
23 3400 Civic Center Boulevard
2d Perelman Center for Advanced Medicine
39 South Pavilion, 12-105
Philadelphia, PA 19104
26
23 3400 Civic Center Boulevard
2d Perelman Center for Advanced Medicine
39 South Pavilion, 12-105
Philadelphia, PA 19104
35
f
13
Education:
21 9 B.A. 1e (Organic Chemistry) c
2c Syracuse University, 1971.
21 9 M.D. 15 (Medicine) c
2f Harvard Medical School, 1975.
c
3
3
3
3
8d
Permanent link21 9 B.A. 1e (Organic Chemistry) c
2c Syracuse University, 1971.
21 9 M.D. 15 (Medicine) c
2f Harvard Medical School, 1975.
c
2 29
21
1e
1d
24
5e
8
2d3 Dr. Shulman is past Chair of the Commission on Cancer and serves on the National Cancer Policy Forum of the National Academy. He is the former Chair of the American Society of Clinical Oncology Quality of Care Committee and the Commission on Cancer’s Quality Integration Committee. Dr. Shulman serves as Senior Oncology Advisor to the non-profit organization Partners In Health (PIH). The PIH mission includes the establishment of national cancer treatment programs with the Ministries of Health in Rwanda, Lesotho, and Haiti, programs for which he plays a seminal leadership role. In addition, he helps to lead the development of the national oncology program in Botswana through the Botswana-UPenn Partnership.
8
107 Dr. Shulman is a former member of ASCO’s International Affairs Committee and their Task Force on Global Oncology as an Academic Career. He led the World Health Organization’s review and revision of their Essential Medicines for Cancer from 2014-2017.
8
88 He received his MD from Harvard Medical School, and trained in Hematology and Oncology at the Beth Israel Hospital in Boston, MA.
62
65
e 29
27
Description of Clinical Expertise
cd Lawrence N. Shulman, MD, is the Associate Director for Special Projects of the Abramson Cancer Center at the University of Pennsylvania, and Co-Director of the Center for Global Oncology.8
2d3 Dr. Shulman is past Chair of the Commission on Cancer and serves on the National Cancer Policy Forum of the National Academy. He is the former Chair of the American Society of Clinical Oncology Quality of Care Committee and the Commission on Cancer’s Quality Integration Committee. Dr. Shulman serves as Senior Oncology Advisor to the non-profit organization Partners In Health (PIH). The PIH mission includes the establishment of national cancer treatment programs with the Ministries of Health in Rwanda, Lesotho, and Haiti, programs for which he plays a seminal leadership role. In addition, he helps to lead the development of the national oncology program in Botswana through the Botswana-UPenn Partnership.
8
107 Dr. Shulman is a former member of ASCO’s International Affairs Committee and their Task Force on Global Oncology as an Academic Career. He led the World Health Organization’s review and revision of their Essential Medicines for Cancer from 2014-2017.
8
88 He received his MD from Harvard Medical School, and trained in Hematology and Oncology at the Beth Israel Hospital in Boston, MA.
62
Description of Other Expertise
186 Dr Shulman has a long history of development and implementation of information technology solutions to improve the efficiency and safety of cancer care delivery. He continues to develop tools to improve data capture in electronic health records (EHRs) and to utilize those and patient reported outcomes to understand treatment and outcomes of real world patients in the US.65
Description of Research Expertise
ae His research includes innovations in cancer care delivery, both in the US and in resource constrained settings, including Rwanda, Lesotho, Botswana and Haiti.e 29
23
de Shulman LN, Hricak H, Eckhardt SG.: Challenges and Opportunities for the US Oncology Workforce. JAMA Oncol. doi:10.1001/jamaoncol.2025.2331 Jul 2025.
11a Shulman LN, Bradley CJ, Winn RA, Yabroff KR.: Cancer Surveillance in the United States in Jeopardy: Leveraging 21st Century Technology to Enhance Public Health. J Clin Oncol. doi: 10.1200/JCO-25-0075 May 2025.
215 Bhangdia K, Natarajan A, Rudolfson N, Verguet S, Castro MC, Dusengimana JV, Shyirambere C, Schleimer LE, Shulman LN, Umwizerwa A, Kigonya C, Butonzi J, MacDuffie E, Fadelu T, O'Neil DS, Nguyen C, Mpunga T, Keating NL, Pace LE.: The association of travel distance and other patient characteristics with breast cancer stage at diagnosis and treatment completion at a rural Rwandan cancer facility. BMC Cancer. doi: 10.1186/s12885-025-13489-2. 25: 146, Jan 2025.
1f3 Bange EM, Coughlin KQ, Li W, Brown TJ, Ragusano D, Balar E, Arasappan D, Nnaji M, Kim E, Alban C, Uppuluri S, Moriarty E, Bange T, Zinck L, Smith D, Josephs M, Harrigan JJ, Cohen RB, Zubka D, Rosin R, Balachandran M, Long Q, Bilger A, Schuchter LM, Mamtani M, Shulman LN, Guerra CE, Mamtani R.: A Text Message Intervention to Minimize the Time Burden of Cancer Care. NEJM Catal Innov Care Deliv. doi:10.1056/CAT.24.0201. 2025.
182 Desai AN, Jacobs E, Ogedegbe O, Rubenfeld G, Berlin J, Shulman L, O'Cearbhaill R, Studenski S, Powell E, Mmeje O, Trueger NS, Chino F, Perlis R, Fihn S, Perencevich E. : The Global Public Health Imperative-Where Do We Go From Here? JAMA Netw Open. 2025 May 1;8(5):e2517283. doi:10.1001/jamanetworkopen.2025 2025.
18d Martei YM, Gurram M, Mokokwe LT, Ngwako N, Kebuang K, Setlhako DI, Vuylsteke P, Bontswanetse B, Segadimo T, Mosepele M, Shulman LN, Barg F, Gaolebale BE.: Baseline Distress and Effectiveness of Survivor Video Narratives on Cancer-Associated Distress in Botswana: A Pilot Study. JCO Glob Oncol. doi: 10.1200/GO-24-00474 2025.
207 Schnoll R, Bekelman JE, Blumenthal D, Asch DA, Buttenheim AM, Chaiyachati KH, Domchek SM, Fayanju OM, Gabriel P, Jenssen BP, Leone FT, McCarthy AM, Nathanson KL, Parikh RB, Rendle KA, Shelton RC, Shulman LN, Takvorian SU, Ware S, Wileyto EP, Beidas RS.: Using the Translational Science Benefits Model to assess the impact of the Penn Implementation Science Center in Cancer Control. J Clin Transl Sci. doi:10.1017/cts.2024.554. 8: e166, Oct 2024.
108 Castillo BS, Boadi T, Han X, Shulman LN, Martei YM.: Racial Disparities in Receipt of Guideline-Concordant Care in Older Adults With Early Breast Cancer. JAMA Netw Open 7: e2441056, Oct 2024.
112 Jacobs L, Shulman L: Cardio-Oncology Care Delivery for All Patients With Cancer Within Academic and Community Settings. J Am Coll Cardiol CardioOnc. 2024, 0 (0) doi: 10.1016/j.jaccao.2023.10.010 2024.
2c
7
1d
1f
Selected Publications
166 Herbst RS, Blumenthal G, Khleif SN, Lippman SM, Meropol NJ, Rosati K, Shulman LN, Smith H, Wang M, Winn RA, Schilsky RL.: Optimizing public-private partnerships to support clinical cancer research. J Natl Cancer Inst. Dec 12:djae279. doi: 10.1093/jnci/djae279 117: 1305-1310, Jul 2025.de Shulman LN, Hricak H, Eckhardt SG.: Challenges and Opportunities for the US Oncology Workforce. JAMA Oncol. doi:10.1001/jamaoncol.2025.2331 Jul 2025.
11a Shulman LN, Bradley CJ, Winn RA, Yabroff KR.: Cancer Surveillance in the United States in Jeopardy: Leveraging 21st Century Technology to Enhance Public Health. J Clin Oncol. doi: 10.1200/JCO-25-0075 May 2025.
215 Bhangdia K, Natarajan A, Rudolfson N, Verguet S, Castro MC, Dusengimana JV, Shyirambere C, Schleimer LE, Shulman LN, Umwizerwa A, Kigonya C, Butonzi J, MacDuffie E, Fadelu T, O'Neil DS, Nguyen C, Mpunga T, Keating NL, Pace LE.: The association of travel distance and other patient characteristics with breast cancer stage at diagnosis and treatment completion at a rural Rwandan cancer facility. BMC Cancer. doi: 10.1186/s12885-025-13489-2. 25: 146, Jan 2025.
1f3 Bange EM, Coughlin KQ, Li W, Brown TJ, Ragusano D, Balar E, Arasappan D, Nnaji M, Kim E, Alban C, Uppuluri S, Moriarty E, Bange T, Zinck L, Smith D, Josephs M, Harrigan JJ, Cohen RB, Zubka D, Rosin R, Balachandran M, Long Q, Bilger A, Schuchter LM, Mamtani M, Shulman LN, Guerra CE, Mamtani R.: A Text Message Intervention to Minimize the Time Burden of Cancer Care. NEJM Catal Innov Care Deliv. doi:10.1056/CAT.24.0201. 2025.
182 Desai AN, Jacobs E, Ogedegbe O, Rubenfeld G, Berlin J, Shulman L, O'Cearbhaill R, Studenski S, Powell E, Mmeje O, Trueger NS, Chino F, Perlis R, Fihn S, Perencevich E. : The Global Public Health Imperative-Where Do We Go From Here? JAMA Netw Open. 2025 May 1;8(5):e2517283. doi:10.1001/jamanetworkopen.2025 2025.
18d Martei YM, Gurram M, Mokokwe LT, Ngwako N, Kebuang K, Setlhako DI, Vuylsteke P, Bontswanetse B, Segadimo T, Mosepele M, Shulman LN, Barg F, Gaolebale BE.: Baseline Distress and Effectiveness of Survivor Video Narratives on Cancer-Associated Distress in Botswana: A Pilot Study. JCO Glob Oncol. doi: 10.1200/GO-24-00474 2025.
207 Schnoll R, Bekelman JE, Blumenthal D, Asch DA, Buttenheim AM, Chaiyachati KH, Domchek SM, Fayanju OM, Gabriel P, Jenssen BP, Leone FT, McCarthy AM, Nathanson KL, Parikh RB, Rendle KA, Shelton RC, Shulman LN, Takvorian SU, Ware S, Wileyto EP, Beidas RS.: Using the Translational Science Benefits Model to assess the impact of the Penn Implementation Science Center in Cancer Control. J Clin Transl Sci. doi:10.1017/cts.2024.554. 8: e166, Oct 2024.
108 Castillo BS, Boadi T, Han X, Shulman LN, Martei YM.: Racial Disparities in Receipt of Guideline-Concordant Care in Older Adults With Early Breast Cancer. JAMA Netw Open 7: e2441056, Oct 2024.
112 Jacobs L, Shulman L: Cardio-Oncology Care Delivery for All Patients With Cancer Within Academic and Community Settings. J Am Coll Cardiol CardioOnc. 2024, 0 (0) doi: 10.1016/j.jaccao.2023.10.010 2024.
2c